Harmony Outcomes: A randomized, double‐blind, placebo‐controlled trial of the effect of albiglutide on major cardiovascular events in patients with type 2 diabetes mellitus—Rationale, design, and baseline characteristics

[1]  Neha J. Pagidipati,et al.  Effects of Once‐Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes , 2017, The New England journal of medicine.

[2]  P. J. Pedersen,et al.  Absorption, metabolism and excretion of the GLP‐1 analogue semaglutide in humans and nonclinical species , 2017, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[3]  K. Mahaffey,et al.  Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes , 2017, The New England journal of medicine.

[4]  Neha J. Pagidipati,et al.  Baseline characteristics of patients enrolled in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL) , 2017, American heart journal.

[5]  K. Khunti,et al.  Efficacy and safety of glucagon‐like peptide‐1 receptor agonists in type 2 diabetes: A systematic review and mixed‐treatment comparison analysis , 2017, Diabetes, obesity & metabolism.

[6]  M. Christensen,et al.  Clinical Pharmacokinetics and Pharmacodynamics of Albiglutide , 2017, Clinical Pharmacokinetics.

[7]  9. Cardiovascular Disease and Risk Management , 2016, Diabetes Care.

[8]  Lawrence A Leiter,et al.  Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. , 2016, The New England journal of medicine.

[9]  John B Buse,et al.  Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. , 2016, The New England journal of medicine.

[10]  M. Pencina,et al.  Rationale and design of the EXenatide Study of Cardiovascular Event Lowering (EXSCEL) trial. , 2016, American heart journal.

[11]  R. Brook,et al.  GLP-1 Agonists and Blood Pressure: A Review of the Evidence , 2016, Current Hypertension Reports.

[12]  S. Madsbad.  Review of head‐to‐head comparisons of glucagon‐like peptide‐1 receptor agonists , 2015, Diabetes, obesity & metabolism.

[13]  S. Solomon,et al.  Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. , 2015, The New England journal of medicine.

[14]  B. Zinman,et al.  Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. , 2015, The New England journal of medicine.

[15]  J. McMurray,et al.  Cardiovascular safety of albiglutide in the Harmony programme: a meta-analysis. , 2015, The lancet. Diabetes & endocrinology.

[16]  S. Solomon,et al.  Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo. , 2015, American heart journal.

[17]  Murray Stewart,et al.  Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study. , 2014, The lancet. Diabetes & endocrinology.

[18]  B. Zinman,et al.  Design of the liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results (LEADER) trial. , 2013, American heart journal.

[19]  V. Basevi,et al.  Standards of Medical Care in Diabetes—2012 , 2011, Diabetes Care.

[20]  G. Bonsel,et al.  Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L) , 2011, Quality of Life Research.

[21]  J. Danesh,et al.  Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. , 2010, Lancet.

[22]  M. Bush,et al.  Safety, tolerability, pharmacodynamics and pharmacokinetics of albiglutide, a long‐acting glucagon‐like peptide‐1 mimetic, in healthy subjects , 2009, Diabetes, obesity & metabolism.

[23]  Sue-Jane Wang,et al.  Some Controversial Multiple Testing Problems in Regulatory Applications , 2009, Journal of biopharmaceutical statistics.

[24]  N. Clark,et al.  Standards of Medical Care in Diabetes: Response to Power , 2006 .

[25]  A. Lambeir,et al.  Dipeptidyl-peptidase IV converts intact B-type natriuretic peptide into its des-SerPro form. , 2006, Clinical chemistry.

[26]  D. Drucker,et al.  A recombinant human glucagon-like peptide (GLP)-1-albumin protein (albugon) mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis. , 2004, Diabetes.

[27]  Kroccollaborativestudygroup.  Blood glucose control and the evolution of diabetic retinopathy and albuminuria. A preliminary multicenter trial. , 1984, The New England journal of medicine.